Intended for healthcare professionals

Letters Pathways to independence

Distancing design of phase III trials from drug company influence

BMJ 2020; 368 doi: (Published 20 January 2020) Cite this as: BMJ 2020;368:m165
  1. Till Bruckner, founder
  1. TranspariMED, c/o Bristol Happy City, Canningford House, Bristol BS1 6BY, UK
  1. tillbruckner{at}

Moynihan and colleagues propose ways to produce healthcare evidence independent of commercial interests.1

The design of pivotal phase III clinical trials is typically discussed in advance between regulators and drug companies, and the subsequent trials are often conducted by contract research organisations directly subcontracted by the drug company. Two small tweaks to this …

View Full Text

Log in

Log in through your institution


* For online subscription